Rapport Therapeutics, Inc. Common Stock (RAPP) is a publicly traded Healthcare sector company. As of May 21, 2026, RAPP trades at $35.69 with a market cap of $1.68B and a P/E ratio of -13.51. RAPP moved +4.04% today. Year to date, RAPP is +29.80%; over the trailing twelve months it is +249.51%. Its 52-week range spans $6.43 to $42.27. Analyst consensus is strong buy with an average price target of $51.71. Rallies surfaces RAPP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes RAPP SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $35.69 |
| Market Cap | $1.68B |
| P/E Ratio | -13.51 |
| EPS | $-2.59 |
| Dividend Yield | 0.00% |
| 52-Week High | $42.27 |
| 52-Week Low | $6.43 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $20.00M |
| Net Income | $-107.28M |
| Gross Margin | 0.00% |
9 analysts cover RAPP: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $51.71.